Trial Profile
A phase 4, monocenter, prospective, randomized, placebo-controlled, double-blind, cross-over mechanistic intervention trial to assess effect of 4-week Ertugliflozin (SGLT-2 inhibitor) therapy on renal (cortical and medullary) oxygenation as determined by BOLD-MRI (R2*) and renal (cortical and medullary) oxygen consumption as determined by positron emission tomography (PET) using ¹¹C-acetate in patients with type 2 diabetes mellitus and healthy controls
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Sep 2023
Price :
$35
*
At a glance
- Drugs Ertugliflozin (Primary)
- Indications Diabetic nephropathies; Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms ROCKIES
- 28 Apr 2023 Status changed from recruiting to completed.
- 30 Mar 2021 Planned End Date changed from 1 Dec 2021 to 1 Jan 2022.
- 30 Mar 2021 Planned primary completion date changed from 1 May 2021 to 1 Dec 2021.